Applications
SIGLEC7, also known as sialic acid-binding immunoglobulin-like lectin 7, has various applications in different fields. In the field of immunomodulation, SIGLEC7 is considered a promising target for regulating immune cell activity. Novel sialic acid derivatives that bind to SIGLEC7 have been discovered, and their synthesis and affinity measurements have been studied. Molecular dynamics simulations have been used to predict the binding modes of these ligands, providing insights into their molecular interactions with the receptor. Additionally, the study highlights the shortcomings of certain force fields used in the simulation of sialoside-based glycomimetics. These findings open up new opportunities for the rational design of SIGLEC7 inhibitors. In the field of CRISPR gene editing, SIGLEC7 is mentioned in the context of disrupting protein expression using double-clicked sgRNA-Cas9 complexes. The study describes a modular approach to CRISPR gene editing, where a functional single guide RNA (sgRNA) is synthesized by stitching together smaller fragments. Chemically modified nucleotides are incorporated into the sgRNA to increase resistance against ribonucleases, leading to improved success in knocking out a gene of interest. The study demonstrates the successful knockout of both SIGLEC-3 and SIGLEC-7 using this approach. In the field of glioma research, SIGLEC7 is identified as one of the inhibitory checkpoints expressed in a cytokine-predominant immunosuppressive class of glioblastoma patients. This class of patients shows increased expression of anti-inflammatory cytokines, enrichment of T cell exhaustion signals, and higher proportions of immunosuppressive cells and inhibitory checkpoints, including SIGLEC7. The study suggests that this immunosuppressive class may be resistant to immune checkpoint blockade therapy, highlighting the need for a comprehensive understanding of the tumor microenvironment to improve immunotherapy techniques. In the field of cancer immunotherapy, SIGLEC7 is mentioned in the context of modulating IgA therapy by neutrophils. Hypersialylated cancer cells interact with inhibitory receptors SIGLEC-7 and SIGLEC-9 on neutrophils, inhibiting neutrophil-mediated tumor killing. Blocking SIGLEC-9 enhances IgA-mediated antibody-dependent cellular cytotoxicity (ADCC) by neutrophils. The study suggests that a combination of CD47 blockade and desialylation may be necessary to optimize cancer immunotherapy, considering the upregulation of checkpoint molecules by tumor cells to evade immune surveillance. Finally, in the field of Behcet's disease research, SIGLEC7 is mentioned as one of the genes that could serve as a combined gene signature for differentiating clinical subtypes of the disease. Gene signatures from diagnostic models, along with genes enriched in angiogenesis and glycosylation pathways, can discriminate between mucocutaneous, ocular, and large vein thrombosis involvement in Behcet's disease. These findings suggest that SIGLEC7, along with other genes, could be potential diagnostic markers for subtype identification in Behcet's disease.
Peyton Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
